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 Transplantation is regarded as the therapy 
of choice for end-stage organ failure; how-
ever, the prolonged acceptance of trans-
planted organs requires long-term use of 
immunosuppressive drugs. Th is treatment 
risks infection and a range of side eff ects, 
which, along with the inexorable chronic 
allograft  injury, limit the life of the graft s 
and the patients. 1 The most appealing 
solution to these problems is the induction 
of transplantation tolerance, defi ned as 
 “ the absence of acute and chronic rejection 
and indefi nite graft  survival with normal 
function in an immunocompetent host. ” 2 
Such a condition has been successfully 
induced in rodent models of solid-organ 
transplantation by several therapeutic 
strategies that, however, turned out to be 
diffi  cult to apply in the clinical setting 
because of intrinsic toxicity. 1 
 Nevertheless, patients with liver and, 
more rarely, kidney grafts that were 
functioning for many years aft er cessa-
tion of immunosuppression have been 
reported. Most of these cases are the 
result of noncompliance or withdrawal 
mandated by drug-associated complica-
tions. 1 Demonstrating  ‘ true ’ tolerance is 
not possible in these patients. Biopsies 
are oft en unavailable to exclude subclin-
ical rejection, and some of these patients 
eventually developed chronic rejection 
or deterioration of graft  function from 
nonimmune causes. In addition, donor-
specifi c immunocompetence, which in 
experimental animals is documented by 
the ability to accept a second graft  of the 
same donor origin while being able to 
reject a third-party graft , cannot be dem-
onstrated  in vivo in humans. Th us the 
less stringent clinical defi nition of oper-
ational tolerance or drug-free long-term 
graft  function has been adopted. 
 Studies on drug-free patients with trans-
plants are very fascinating, as they inspire 
us by clearly demonstrating that tolerance 
is a biological possibility in humans, at 
least transiently. In addition, understand-
ing the mechanisms underlying spontane-
ous operational tolerance is of great 
importance, as it may help us to fi nd spe-
cifi c markers to guide progressive immu-
nosuppressive drug minimization in 
selected patients, as well as to develop and 
monitor new tolerance induction proto-
cols in humans. 
 Several studies in recent years have largely 
investigated the phenotype of peripheral 
blood immune cells in operationally toler-
ant patients with the goal of disclosing the 
immunological signature behind opera-
tional tolerance, with disparate and oft en 
confl icting results. 3 – 8 A moot point in such 
studies is the choice of adequate compara-
tors, as the ideal control to operationally 
tolerant patients, that is, non-immunosup-
pressed patients rejecting the graft , is obvi-
ously hard to achieve. Th us, operationally 
tolerant patients have been compared with 
those with chronic rejection, who have a 
transplant but are under immunosuppres-
sion and likely display an infl ammatory 
response; or with patients with stable graft  
function under immunosuppression, who 
share graft  function stability with opera-
tionally tolerant patients but are immuno-
suppressed; or with healthy individuals, 
who share with operationally tolerant 
patients the absence of immunosuppression 
but have not received a graft . 
 In a study in 16 operationally tolerant 
European liver transplant recipients, 3 
microarray profi ling in peripheral blood 
mononuclear cells identified a gene 
expression signature that could discrim-
inate tolerant from immunosuppression-
dependent recipients. Genes expressed 
by    T cells and coding for natural killer 
receptors were upregulated in peripheral 
blood of tolerant patients. In addition, 
as compared with either non-tolerant 
immunosuppressed patients or healthy 
individuals, tolerant patients exhibited 
greater numbers of CD4   +   CD25   +  
regulatory T cells and an expansion of 
the V  1   +   subset of    T cells, which 
resulted in a reversal of the normal 
V  1 / V  2 ratio. Th e same increases of 
CD4   +   CD25 high regulatory T cells and of 
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V  1   +   cells were reported in operation-
ally tolerant Japanese pediatric recipients 
of living-donor livers. 4 
 In kidney transplantation, most work 
has been done by Soulillou and his group, 
who have collected the largest number of 
operationally tolerant kidney transplant 
recipients. At variance with studies in 
liver-tolerant patients, they found no dif-
ference in the number of peripheral 
CD4   +   CD25 high regulatory T cells 
between tolerant kidney recipients, 
immunosuppressed patients with stable 
graft  function, and healthy individuals. 5 
   T cells were not investigated in kidney-
tolerant patients, but a study on T-cell 
receptor (TCR) V  chains showed that 
most of these patients displayed a 
strongly altered TCRV  chain usage as 
compared with other transplant recipi-
ents and healthy controls. 6 Th e T cells 
with skewed TCR usage did not accumu-
late Th 1 (interleukin (IL)-2, interferon-  ) 
nor Th 2 (IL-10, IL-13) cytokine tran-
scripts but displayed a cytokine profi le 
much closer to that of normal individuals 
than to that of chronically rejecting 
patients. In another paper, 7 operationally 
tolerant patients showed the same CD8   +  
lymphocyte profi le as healthy individuals 
in terms of percentages of CD8   +   CD28  –  
effector cells, sensitivity to apoptosis, 
proliferative capacity, and cytotoxicity. 
Thus, T cells from drug-free kidney 
transplant patients showed a quiescent 
phenotype similar to that of healthy sub-
jects rather than a specifi c tolerant signa-
ture ( Figure 1 ). 
 As they report in this issue of  Kidney 
International , the same group (Pallier 
 et al. 9 ) investigated the B-cell phenotype 
in operationally tolerant kidney transplant 
patients. Th is subject is of great relevance, 
as growing interest is emerging in B cells 
as key coordinators of the immune 
response. Besides producing antibodies 
and mediating optimal CD4   +   T-cell acti-
vation, B cells have been recently shown 
to negatively regulate auto- and alloim-
munity and inflammation in several 
mouse models. 10,11 Regulatory B cells that 
produce IL-10 are predominantly local-
ized within a rare CD1d high CD5   +  
B-cell subset in mice. 10 Rare circulating 
B cells that produce IL-10 have been iden-
tifi ed in humans as well. 10 
 Pallier  et al. 9 found higher numbers of 
total, activated (IgD   +   CD38   +   Bm2), and 
memory (IgD  –  CD38  – /  +   EBm5 / Bm5) 
B cells in patients with operational toler-
ance than in immunosuppressed patients 
with stable graft  function. Th e presence 
of higher numbers of memory IgD  –
  CD38  – /  +   EBm5 / Bm5 B cells expressing 
activation markers led Pallier  et al. 9 to 
conclude that the pool of memory acti-
vated B cells expanded in tolerant 
patients. However, an eff ect of immuno-
suppression on B-cell number and phe-
notype cannot be excluded, as most 
activation markers differed only with 
respect to immunosuppressed patients 
with transplants, not with respect to 
healthy subjects ( Figure 1 ). 
 Pallier and colleagues 9 then reanalyzed 
the transcription profile previously 
obtained by pangenomic microarrays of 
peripheral blood leukocytes from opera-
tionally tolerant patients 8 and focused on 
gene sets related to B-cell pathways. Th ey 
found a signifi cant upregulation of genes 
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 Figure 1  |  Visual representation of comparisons of T-cell and B-cell phenotype and function between operationally tolerant (DF (drug-free )) 
kidney graft recipients and healthy volunteers (HV), or DF patients and immunosuppressed patients with stable graft function (STA), or 
DF patients and immunosuppressed patients with chronic rejection (CR), as reported in the literature and in particular by Pallier  et al. 9 
Statistically significant differences are shown in red (higher values of the specific parameter), blue (lower values), and striped red and blue (altered 
T-cell receptor usage or autoantibody profile). Green, no difference; grey, no data available. AU, arbitrary units; IL, interleukin; n ° , numbers; TCR, T-cell 
receptor; TGF-  1, transforming growth factor-  1; TNF-  , tumor necrosis factor-  . It appears that cells from operationally tolerant kidney graft recipients 
are very similar to those from healthy volunteers. 
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involved in B-cell cycle, proliferation, 
development, and maturation in tolerant 
patients as compared with immunosup-
pressed recipients with stable graft  func-
tion. The accumulation of B-cell 
transcripts found by microarray analysis 
is consistent with the abnormal expansion 
of the B-cell pool. 
 Pallier and colleagues 9 also analyzed 
expression levels of molecules known to 
be involved in inhibitory / regulatory B-cell 
profiles and identified two molecules 
whose transcript levels were overexpressed 
in peripheral blood leukocytes from oper-
ationally tolerant patients, namely Fc  
receptor IIB (CD32b), an immunorecep-
tor tyrosine-based inhibition motif 
transducing an inhibitory signal that 
blocks B proliferation, 12 and BANK1, a 
negative modulator of CD40-mediated 
AKT activation. 13 Th e latter fi ndings were 
not related to lack of immunosuppression, 
as the two transcripts also diff ered with 
respect to healthy volunteers. CD32b and 
BANK1 upregulation likely refl ected the 
expansion of the B-cell pool in operation-
ally tolerant patients, as diff erences were 
lost when the expression of CD32b and 
that of BANK1 were measured selectively 
in B cells ( Figure 1 ). 
 The most interesting finding of this 
study is that operationally tolerant patients 
have in their blood a higher percentage of 
B cells expressing CD1d and CD5, two 
molecules potentially involved in B-cell 
regulatory phenotype. 10 Pallier and col-
leagues 9 hypothesized that B cells with 
inhibitory phenotype may be involved in 
some regulatory / controlling processes 
that contribute to operational tolerance. 
However, this remains an unproved pos-
sibility, as they did not fi nd any refl ection 
of this peculiar B-cell phenotype in 
immune function. Actually, despite high 
CD32b and BANK1 expression, B cells of 
operationally tolerant patients responded 
normally to polyclonal stimulation, by 
upregulating activation markers and 
releasing infl ammatory cytokines, and did 
not produce  ‘ tolerizing ’ cytokines, includ-
ing IL-10, which is typically released by 
CD1d high CD5   +   B cells. 10 Along the same 
lines, operationally tolerant patients had 
levels of circulating autoantibodies 
comparable to those seen in the other 
groups with transplants. Th e antigenic 
target profi le of the autoantibodies from 
operationally tolerant patients partially 
diff ered from those of the other groups, 
with a higher prevalence of autoanti-
bodies against 48 unique proteins and a 
lower titer against 44 other unique 
proteins. Th e link between the altered 
autoantibody profile and tolerance 
remains obscure, as the target proteins 
could not be attributed to a specifi c path-
way or biological process. 
 One could speculate that the putative 
regulatory B cells in operationally tolerant 
patients act on donor-specifi c immune 
processes without aff ecting unselective 
immune competence. In this respect, 
however, the presence of anti-donor anti-
bodies in the serum of two of 12 opera-
tionally tolerant patients did not seem to 
indicate a lower anti-donor B-cell activity. 
Th ese results are in line with published 
data from four patients who received 
combined kidney and bone marrow 
transplantation, in whom immunosup-
pressive therapy was successfully discon-
tinued. Indeed, two of them developed 
both autoantibodies and donor-specifi c 
alloantibodies. 14 
 Th e results of the report by Pallier  et al. 9 
are far from being conclusive, and further 
functional studies with donor stimulator 
antigen-presenting cells or donor-type 
synthetic major histocompatibility 
complex peptides in coculture or delayed-
type hypersensitivity tests with  ‘ tolerizing ’ 
B cells are needed to verify whether 
B cells from operationally tolerant 
patients indeed have regulatory proper-
ties. Further studies are also required to 
clarify the significance of the peculiar 
auto-alloantibody response in operation-
ally tolerant patients. 
 Finding that patients with drug-free 
long-term kidney graft function dis-
played a particular B-cell phenotype 
with some features of regulatory B cells 
is, in any case, intriguing and opens the 
way to future studies to disclose the 
B-cell signature of tolerance. 
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